Plans expect cell and gene therapies to pose a moderate or major financial challenge in the next two to three years, according to a new survey of pharmacy benefit leaders by PSG.

Here’s what you missed this week on Managed Healthcare Executive.

Children and young adults living in states with the biggest drops in Medicaid coverage experienced more prescription disruptions for their chronic conditions than those living in states with smaller drops, according to a new study by researchers at the University of Michigan.

A new study by JAMA Health Forum found that universal annual depression screening for young adults during primary care visits is cost-effective and can result in greater benefits if paired with better treatment access and lower costs, particularly for multiracial and Hispanic females.

If approved, Wegovy would be the first oral GLP-1 drug to treat obesity.

In mice with human Merkel cell carcinoma, pyrvinium pamoate significantly reduced tumor growth, potentially offering a new way to treat this aggressive skin cancer.

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Cigna is raising its full-year 2025 outlook, with a consolidated adjusted income from operations to be about $29.60 per share.

A new report suggests combining the antimalarial drug with aminoglycosides could enhance the latter’s efficacy, which could also have important safety implications.

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Payers and providers, often depicted as rivals, are on the same side when it comes to the 340B program that allows some hospitals to buy drugs at steep discounts, according to Milliman experts.

The new research center at the University of Michigan and Oregon Health & Science University intends to develop a clinical trial platform that will be used to test several heart and kidney therapies in people living with type 1 diabetes.

During the first quarter of 2025, CVS Health recorded a premium deficiency reserve of $448 million within its individual exchange business.

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

The victims of intimate partner violence were found to have more menopause symptoms, according to the results of a Turkish study published this month in Menopause.

An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic pulmonary fibrosis.

The actor expressed some regret as well as gratitude in talking about the death of his 33-year-old son from a rare form of sarcoma.

Insurance hurdles and the complexities of prior authorization create barriers to care, according to oncologists in a new survey by Sermo.

Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg through its NovoCare Pharmacy.

The margins are small, and the services they provide must be “high touch.” 340B participation and cost-plus pricing are floated as tactics the pharmacies might use to improve their economics.

Managed Healthcare Executive asked several experts in healthcare and managed care to share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.

Patients and providers found common ground on the importance of correct billing estimates but did not see eye to eye in terms of digital scheduling tool use, according to a new survey by Experian Health.